Shanghai, China – 3 July, 2015 - Shanghai MicroPort Orthopedics Co ("MicroPort® Orthopedics") announced that its second generation medial-pivot Evolution™ Medial-Pivot Knee System ("Evolution™") was recently awarded registration certificate from China Food and Drug Administration ("CFDA").
The Evolution™ is designed to treat non-inflammatory joint diseases, including osteoarthritis, traumatic arthritis and ischemic necrosis; arthritic diseases such as rheumatoid arthritis; functional deformity; some treatment or device failures; and some fractures that other technologies can't cure. As one of the well-known knee systems in the world, the Evolution™ has gained high market recognition after launched in the US in 2010 and subsequently sold to Europe and Japan.
Built on over 16 years of excellent clinical history of the Advance® Medial-Pivot Knee System ("Advance®"), the Evolution™ is designed to replicate the movement and stability of a normal, healthy knee by incorporating a patented ball-in-socket feature on the medial side. To offer better implant fit for patients, it features an expanded number of implant sizes and the anatomic tibial base.
With its launch in the China market, MicroPort® Orthopedics will offer more solutions for patients, which will help reinforce the brand image and increase market share for the company.